

Date and Time:	25th May 2012; 10.30 – 16.30hrs
-----------------------	---

Minutes:		
Guideline Development Group Meeting		
Place:	<i>Boardroom, Level 5, 180 Great Portland Street, London, W1W 5QZ</i>	
Present:	<p>Philip Conaghan (Chair) Mark Porcheret (MP) Elspeth Wise (EW) Ian Bernstein (IB) Fraser Birrell (FB) Michael Doherty (MD) Peter Kay (PK) Rob Middleton (RM) Brian Lucas (BL) Krycia Dziedzic (KD) Weiya Zhang (WZ) Erika Baker (EB) Richard Frearson (RF) Tony Whiting (TW) Jo Cumming (JC)</p> <p>Dave Wonderling, Health Economics Lead (DW) Smita Padhi, Research Fellow (SP) Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN) Margaret Constanti, Health Economist (MC) Sue Latchem, Guideline Lead and Operations Director (SL) Paul Miller, Information Scientist (PM)</p>	
Co-opted experts		
Jens Foell		
Apologies:		
Claire Turner, NICE Guidelines Commissioning Manager (CT) Sara Buckner, Research Fellow (SB)		
Observers:		
Linda Seymour (am only)		
Declarations of Interest		

PC

Declared a non personal pecuniary interest:

Attended the OMERACT meeting, May 2012 in the USA. Travel and accommodation was paid by OMERACT.

MD

Declared personal non pecuniary interests:

WZ and he co-supervise a PhD student, who is undertaking a systematic review and meta-analysis of placebo response in RCTs of complimentary and alternative treatments for OA, which includes acupuncture. The student is funded by a grant from the Chinese Government.

He attended the OARSI meeting in Barcelona in April 25-28. His travel, registration and accommodation was funded by OARSI. He received the OARSI Clinical Research Award for 2012, which included a personal prize of \$2000, which was given to the department

He will be attending EULAR in Berlin in June 5-9. reasonable travel, registration and accommodation will be paid by EULAR since he is an invited speaker. In addition to speaking in the main programme (on management of gout) he will be attending meetings with other collaborators in relation to the OA Trial Bank initiative (no payment involved) and EULAR recommendations for non-pharmacological management of OA (no payment involved).

He was also an invited speaker at the British Pain Society (BPS) at Liverpool 25 April 2012 for "Impact of context in the management of chronic pain" . Travel and hotel expenses were covered by the BPS.

KD

Declared personal non-pecuniary interests: Attended OMERACT meeting 13-18th May 2012 to discuss outcome measures for trials in hand osteoarthritis.

Attended the Osteoarthritis Research Society International, reasonable travel and accommodation expenses were paid by the Arthritis Research UK National Primary Care Centre, her work place.

Appointed joint lead for the Musculoskeletal Comprehensive Local Research Network (CLRN) in the North West Midlands.

Grant holder on an acupuncture study (Whitehurst study) being conducted at Keele University. Funding paid into University account.

WZ

Declared personal non pecuniary interests:

One of his PhDs is currently undertaking meta-analysis of the placebo effect in acupuncture therapy. This is part of his thesis on "Comparison of the proportion of the placebo effect in trials for osteoarthritis'.

Invited to give a talk on Safety of NSAIDs for the Expert Panel Meeting sponsored by Daiichi-Sankyo, Japan at the EULAR Annual Congress, Berlin 6-9 June 2012. Daiichi-Sankyo will pay reasonable expenses for the hotel (2 nights) and flight cost for his trip to Berlin. Daiichi-Sankyo produces loxoprofen, both oral and topical formulations, which mainly sales in Asia and America (mainly south).

EW

Declared personal non-pecuniary interests: Attended the BSR Annual Meeting In Glasgow in May. The BSR accepts sponsorship from different drug companies. She did not have to pay an

entry fee as she was chairing a session.

She has also attended a meeting aimed at podiatrists about assessing feet biomechanics. It was run by Langer (a private company that sells insoles) although Elspeth did have to pay to attend. She attended a half day dermatology session run by Astellas Pharmaceuticals.

RM

Declared a personal non pecuniary interest:

He attended the London Hip Meeting as speaker and chair of a session. His standard class rail travel will be paid by the conference organisers.

JF

Declared non personal pecuniary interest

He is a member of the council in BIMM (British Medical Acupuncture Society) and is involved in postgraduate teaching, involving joint injections and acupuncture.

1. Philip Conaghan welcomed the group to the third meeting of this GDG. The GDG members introduced themselves as a new co-opted expert was present at the meeting. Philip Conaghan asked the GDG for any new DOIs since GDG meeting 1.

2. Dr Jens Foell, co-opted expert to the GDG presented an overview of the use of acupuncture in OA and issues with the evidence base.

3. Smita Padhi and Margaret Constanti presented the clinical and cost effectiveness evidence related to the use of acupuncture in the management of OA. Dr Jens Foell was present during the discussions of the evidence as co-opted expert. The GDG discussed whether the updated evidence base would warrant a change to the recommendation from CG59.

4. Smita Padhi and Margaret Constanti presented the revised clinical and cost effectiveness evidence related to the use of nutraceuticals in the management of OA, which had been provisionally discussed at GDG meeting 2. The GDG discussed whether the updated evidence base would warrant a change to the recommendation from CG59.

5. Margaret Constanti presented the health economics priorities in terms of modelling work for the guideline update.

6. Vanessa Delgado Nunes presented the hyaluronan injections protocol and the evidence review will be delivered at GDG meeting 4.

The meeting closed at 16.50hrs.

Date, time and venue of the next meeting

4th July 2012, 10:30 – 16:30hrs.

